Table 3.
Histoclinical comparison of the two basal subgroups defined with the immune metagene in the independent validation series
| Characteristics (N) | Immune-High n = 122 | Immune-Low n = 396 | p-value | OR (95%CI) |
|---|---|---|---|---|
| N (% of evaluated cases) | ||||
| Age (372) | 0.71* | |||
| ≤ 50 years | 53 (62%) | 169 (59%) | 1 | |
| > 50 years | 33 (38%) | 117 (41%) | 1.11 (0.66-1.89) | |
| Pathological tumor size, pT (394) | 0.11* | |||
| pT1 | 32 (33%) | 73 (24%) | 1 | |
| pT2-4 | 64 (67%) | 225 (76%) | 1.54 (0.9-2.6) | |
| Pathological lymph node status, pN (420) | 0.90* | |||
| negative | 62 (65%) | 208 (64%) | 1 | |
| positive | 33 (35%) | 117 (36%) | 1.06 (0.64-1.77) | |
| Tumor grade (420) | ND | |||
| SBR 1 | 0 (0%) | 13 (4%) | ||
| SBR 2-3 | 103 (100%) | 304 (96%) | ||
| IHC ER status (434) | 0.57* | |||
| negative | 73 (77%) | 269 (79%) | 1 | |
| positive | 22 (23%) | 70 (21%) | 0.86 (0.49-1.57) | |
| Lymphocyte infiltrate (56) | 0.51* | |||
| absent | 6 (46%) | 14 (33%) | 1 | |
| present | 7 (54%) | 29 (67%) | 1.76 (0.41-7.48) | |
| Adjuvant chemotherapy (354) | 0.43* | |||
| no | 49 (64%) | 162 (58%) | 1 | |
| yes | 28 (36%) | 115 (42%) | 1.24 (0.72-2.18) | |
| Adjuvant hormone therapy (269) | 0.11* | |||
| no | 59 (91%) | 197 (97%) | 1 | |
| yes | 6 (9%) | 7 (3%) | 0.40 (0.12-1.46) | |
| Follow-up (months, median) (380) | 95 | 89 | 0.44** | |
| Relapses (380) | 25 (26.3%) | 133 (46.7%) | 4.77 E-04* | 0.41 (0.23-0.70) |
| 5-year DFS (380) | 78% | 54% | 1.6 E-04*** | |
N, number of tumor samples - out of the 2515 samples - with available information for the corresponding characteristic, *, Fisher's exact test; **, Mann-Whitney test; ***, log-rank test; ND, not done.